Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 90-98

  Lee, Richard J ^a   Smith, Matthew R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bone metastasis; cabozantinib; MET; prostate cancer; VEGFR

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CABOZANTINIB; DOCETAXEL; ESTRAMUSTINE; LENALIDOMIDE; MEDRONATE TECHNETIUM TC 99M; MITOXANTRONE; PREDNISONE; PROTEIN MCL 1; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SUNITINIB; TASQUINIMOD; VASCULOTROPIN RECEPTOR 2;

BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL FUNCTION; COMPUTER AIDED DESIGN; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; OSTEOBLAST; OVERALL SURVIVAL; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84873812285     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318281e280     Document Type: Review

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29: 3705-3714.
3. Clarke NW, McClure J, George NJ. Osteoblast function and osteomala-cia in metastatic prostate cancer. Eur Urol. 1993;24:286-290.
4. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA. 1996;93:7644-7648.
5. Adamopoulos IE, Xia Z, Lau YS, et al. Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochem Biophys Res Commun. 2006;350:478-483.
6. Tsai S-Y, Huang Y-L, Yang W-H, et al. Hepatocyte growth factor-induced BMP-2 expression is mediated by c-MET receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts. Int Immunopharmacol. 2012;13:156-162.
7. Taichman RS, Reilly MJ, Verma RS, et al. Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors. Br J Haematol. 2001;112:438-448.
8. Deckers MML, Karperien M, van der Bent C, et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology. 2000;141:1667-1674.
9. Street J, Lenehan B. Vascular endothelial growth factor regulates osteo-blast survivalVevidence for an autocrine feedback mechanism. J Orthop Surg Res. 2009;4:19.
10. Marini M, Sarchielli E, Toce M, et al. Expression and localization of VEGF receptors in human fetal skeletal tissues. Histol Histopathol. 2012;27:1579-1587.
11. Trebec-Reynolds DP, Voronov I, Heersche JNM, et al. VEGF-A expression in osteoclasts is regulated by NF-JB induction of HIF-1>. J Cell Biochem. 2010;110:343-351.
12. van Leenders G, van Balken B, Aalders T, et al. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate. 2002;51:98-107.
13. Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-MET: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007;67:967-975.
14. Humphrey PA, Zhu X, Swanson PE, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147:386-396.
15. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the MET receptor in prostate cancer metastasis to bone. Urology. 2002;60:1113-1117.
16. Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol. 2006;21:857-865.
17. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997; 157:2329-2333.
18. Duque JLF, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523-527.
19. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001;61:2533-2536.
20. George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005;11:1815-1820.
21. Zhang S, Zhau H, Osunkoya A, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1Ydependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 2010;9:9.
22. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res. 2005; 11:5223-5232.
23. Brown MS, Chu GH, Kim HJ, et al. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun. 2012;33:384-394.
24. Picus J, Halabi S, Kelly WK, et al, for Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. Cancer. 2011;117:526-533.
25. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540.
26. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for meta-static castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21:319-324.
27. Michaelson MD, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009;20:913-920.
28. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2011; 29(suppl). Abstract 4515.
29. 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of suni-tinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012;53:1670-1675.
30. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endo-thelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77:78-86.
31. Petrylak DP, Fizazi K, Sternberg CN, et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL Trial. ESMO 2012 Congress 2012. Abstract LBA24.
32. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022-4028.
33. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
34. Ryan CJ, Rosenthal M, Ng S, et al. A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitox-antrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2012; 30(suppl 5). Abstract 115.
35. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298-2308.
36. Smith MR, Sweeney C, Rathkopf DE, et al. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol. 2012;30(suppl). Abstract 4513.
37. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozanti-nib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-2666.
38. Schoffski P, Elisei R, Muller S, et al, Group ES. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozan-tinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol. 2012(suppl). Abstract 5508.
39. Choueiri TK, Pal SK, McDermott DF, et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol. 2012;30(suppl). Abstract 4504.
40. Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;29(suppl). Abstract 5008.
41. Cohn AL, Kelley RK, Yang T-S, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl 4). Abstract 261.
42. Gordon MS, Kluger HM, Shapiro G, et al. Activity of cabozantinib (XL184) in metastatic melanoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl). Abstract 8531.
43. Winer EP, Tolaney S, Nechushtan H, et al. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl). Abstract 535.
44. Hellerstedt BA, Edelman G, Vogelzang NJ, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl). Abstract 7514.
45. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2012; [epub ahead of print].
46. Lee RJ, Michaelson MD, Saylor PJ, et al. Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: a dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol. 2012;30(suppl). Abstract 4566.
47. Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials. 2001;22:117-125.
48. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-MET acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090-10100.
49. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-MET and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012; 2:270-287.